Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000624158 | SCV000740927 | likely pathogenic | Inborn genetic diseases | 2021-07-29 | criteria provided, single submitter | clinical testing | The c.695G>A (p.R232Q) alteration is located in exon 9 of the NMNAT2 gene. This alteration results from a G to A substitution at nucleotide position 695, causing the arginine (R) at amino acid position 232 to be replaced by a glutamine (Q). Based on data from gnomAD, the A allele has an overall frequency of <0.01% (3/251452) total alleles studied. The highest observed frequency was <0.01% (3/113734) of European (non-Finnish) alleles. This amino acid position is highly conserved in available vertebrate species. The p.R232 amino acid is located in the NAD binding pocket of the NMNAT2 enzyme and is found to be crucial for the function of the protein due to its direct interaction with NAD. Homology modeling of this amino acid alteration conducted internally at Ambry Genetics using the published crystal structure of the homologous NMNAT3 protein (Zhang, 2003) indicated that this alteration would disrupt the interaction of NMNAT2 with NAD and thereby its function in the biosynthesis of NAD. This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic. |